Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brandon Kaye has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety

    by Brandon Kaye, Laura Kehoe, Nikhil Dholaria, Mohammadmahdi Sabahi, Alireza Soltani Khaboushan, Diego T Soto Rubio, Fayyadh Yusuf, Hoon Choi, César Carballo Cuello, Puya Alikhani

    Purpose Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. Methods Following PRISMA guidelines, a systematic search was conducted across Embase, Scopus, Web of Science, and PubMed through September 15th, 2024. Patient demographics, disease control, survival, and toxicity were analyzed using R. A meta-analysis was conducted using a random-intercept logistic regression model to evaluate the effectiveness of adjunctive IT for spine tumors. The quality of included studies assessed using the Methodological Index for Non-Randomized Studies (MINORS). Results A total of 416 articles were screened, with 17 included for qualitative analysis. The studies included 727 patients, with excluding cases of unknown primary origin, the most common primary tumor types were lung cancer, followed by renal cell carcinoma, and melanoma. The most common IT treatments in studies that reported specific types were anti-PD-L1, followed by anti-PD-1 treatments. Meta-analysis showed tumor control rates of 80% (95% CI: 71–87%) following adjunctive IT and the pooled toxicity rate was 5% (95% CI: 1–26%), both with low heterogeneity (I² = 0%). With a maximum follow-up period of 97 months on patients with available data, there were 65 recorded deaths (65.7%) which were all in patients with metastatic spine tumors and no death were recorded in primary spine tumors and the log-rank test indicated a significantly higher overall survival (OS) rate for adjunctive IT in patients with primary spine tumors compared to those with metastatic spine tumors (P< 0.0001). The OS rates were 75%, 57%, 38%, 26%, and 16% at 6-, 12-, 24-, 36-, and 60 months post-IT, respectively. Conclusion When used as an adjuvant treatment, IT is associated with a high rate of tumor control and a low rate of toxicity in patients with spinal metastases. Additionally, there is a significant improvement in OS for patients with primary spine tumors compared to those with metastatic spine tumors as an adjuvant treatment. Future studies are warranted to further elucidate the benefits and risks of IT in this patient population as a primary treatment modality.


  • Surgical Posture with Microscopic Versus Exoscopic Visualization in Anterior Cervical Procedures

    by Dorian M. Kusyk, Seung Jeong, Ethan Fitzgerald, Brandon Kaye, Jenna Li, Richard Williamson, Alexander K. Yu


  • Chiari Malformation Type 1 and Semi-Sitting Position—A Suitable Alternative for Patients with High BMI

    by Raphael Bastianon Santiago, Brandon Kaye, Vivian Hagerty, Mauricio Mandel, Rocco Dabecco, Assad Ali, Michal Obrzut, Juan Botero, Hamid Borghei-Razavi, Badih Adada


  • Open Access

    The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma

    by Brandon Kaye, Assad Ali, Raphael Augusto Correa Bastianon Santiago, Bilal Ibrahim, Julio Isidor, Hany Awad, Mohammadmahdi Sabahi, Michal Obrzut, Badih Adada, Surabhi Ranjan, et al.

    Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore this relationship in glioblastoma patients. Methods: Two hundred ninety-three consecutive patients with IDH wild-type GBM were included in the analysis. The amplification status of EGFR was measured using fluorescence in situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through chart review. Molecular data were obtained through the surgical pathology report at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not significantly correlated with VTE risk overall (p = 0.2001). There was no statistically significant association between VTE and EGFR status after controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was associated with an increased VTE risk in subjects greater than 60 years of age (p = 0.048). Conclusions: There was no significant difference in occurrence of VTE in patients with glioblastoma, regardless of EGFR amplification status. Patients older than 60 years of age with EGFR amplification experienced a lower rate of VTE, contrary to some reports on non-small-cell lung cancer linking EGFR amplification to VTE risk.


  • Endoscopic endonasal optic nerve sheath decompression (EONSD) for idiopathic intracranial hypertension: Technical details and meta-analysis

    by Romel Corecha Santos, Bhavika Gupta, Raphael Bastianon Santiago, Mohammadmahdi Sabahi, Brandon Kaye, Rocco Dabecco, Michal Obrzut, Badih Adada, Nathalia Velasquez, Hamid Borghei-Razavi


  • Open Access

    Regulation of CD4 T Cell Responses by the Transcription Factor Eomesodermin

    by Kunal Dhume, Brandon Kaye, K. Kai McKinstry

    Central to the impacts of CD4 T cells, both positive in settings of infectious disease and cancer and negative in the settings of autoimmunity and allergy, is their ability to differentiate into distinct effector subsets with specialized functions. The programming required to support such responses is largely dictated by lineage-specifying transcription factors, often called ‘master regulators’. However, it is increasingly clear that many aspects of CD4 T cell immunobiology that can determine the outcomes of disease states involve a broader transcriptional network. Eomesodermin (Eomes) is emerging as an important member of this class of transcription factors. While best studied in CD8 T cells and NK cells, an increasing body of work has focused on impacts of Eomes expression in CD4 T cell responses in an array of different settings. Here, we focus on the varied impacts reported in these studies that, together, indicate the potential of targeting Eomes expression in CD4 T cells as a strategy to improve a variety of clinical outcomes.


  • Open Access

    Wide Dissection Trans-Sulcal Approach for Resection of Deep Intra-Axial Lesions in Eloquent Brain Areas

    by Brandon Kaye, Raphael Augusto Correa Bastianon Santiago, Gerard MacKinnon, Rocco Dabecco, Bilal Ibrahim, Assad Ali, Romel Santos, Phillip Johansen, Surabhi Ranjan, Michal Obrzut, et al.

    Introduction: Resection of intra-axial tumors (IaT) in eloquent brain regions risks major postoperative neurological deficits. Awake craniotomy is often used to navigate these areas; however, some patients are ineligible for awake procedures. The trans-sulcal approach (TScal) was introduced to reduce parenchymal trauma during tumor resection. We report our experiences utilizing TScal for resection of deep IaT located in eloquent areas. Materials and Methods: This is a single-center retrospective analysis of patients who underwent IaT resection in eloquent areas via TScal from January 2013 to April 2021. Seventeen cases were reviewed, and relevant data was collected. Fluorescence-guided surgery with 5-aminolevulinic acid (ALA) and intraoperative ultrasound was performed in some cases. Results: Seventeen patients (10 males, 7 females) averaging 61.2 years-old (range, 21–76) were included in this study. Average length of stay was 4.8 days, and only 2 patients (11.8%) required hospital readmission within 30 days. Gross total resection (GTR) was achieved in 15 patients (88.2%), while subtotal resection occurred in 2 patients (11.8%). Eleven patients (64.7%) reported full resolution of symptoms, 4 patients (23.5%) reported deficit improvement, and 2 patients (11.8%) experienced no change from their preoperative deficits. No patient developed new permanent deficits postoperatively. Discussion: GTR, preoperative deficit reduction, and complications were comparable to awake craniotomy and other TScal studies. Ancillary intraoperative techniques, such as brain mapping, 5-ALA and intraoperative ultrasound, are afforded by TScal to improve resection rates and overall outcomes. Conclusions: TScal can be an option for patients with deep lesions in eloquent areas who are not candidates for awake surgeries.